Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health Inc reported that Vanguard Capital Management filed a Schedule 13G as of June 30, 2026, disclosing beneficial ownership of 11,188,807 shares of common stock, representing 5.01% of the class. Vanguard has sole voting power over 1,647,423 shares and sole dispositive power over 11,188,807 shares, with no shared voting or dispositive power. The filing aggregates holdings across Vanguard Capital Management LLC and specified affiliated entities and funds; no other single person has an interest in more than 5% of the class through these holdings.
BlackRock, Inc. reports a significant passive ownership position in Hims & Hers Health Inc. Class A stock. BlackRock beneficially owns 26,496,218 shares, representing 11.9% of the Class A shares outstanding. All of these shares are reported as held by certain business units of BlackRock and its subsidiaries and affiliates.
BlackRock has sole voting power over 25,979,274 shares and sole dispositive power over the full 26,496,218 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single underlying person is reported to hold more than five percent of Hims & Hers Health Inc.’s outstanding common shares.
Hims & Hers Health CFO Oluyemi Okupe exercised stock options for 7,163 Class A shares at $5.0100 on July 17, 2026, then sold 7,163 shares at a weighted-average price of $31.9933 under a Rule 10b5-1 plan adopted May 21, 2025. After these transactions he holds 284,321 Class A shares directly, 7,853 shares indirectly through a separate property trust, and 95,198 stock options remaining.
Hims & Hers Health, Inc. announced that Irene BecklundChief Accounting OfficerPrincipal Accounting Officer
Becklund has served as Chief Accounting Officer since April 2025 and as Principal Accounting Officer since November 2021. The company entered into an advisory agreement with her, effective October 10, 2026, under which she will continue supporting the company in an advisory capacity through July 10, 2027.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported an option exercise and related share sale in Class A Common Stock. Okupe exercised stock options to acquire 7,163 shares at a price of $5.0100 per share, then sold 7,163 shares at an average price of $36.4863 per share.
These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025. Following the transactions, Okupe holds 284,321 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021, along with 102,361 stock options remaining outstanding.
Issuer: HIMS Holdings Corp. Reported Form 144 notices show multiple sales of Common stock by Oluyemi Okupe, executed on various dates in April–June 2026. Individual transactions range from 1,438 shares to 55,383 shares, with corresponding proceeds shown in the filing.
The filing indicates some shares were acquired as compensation via stock options and disposed via cashless exercise / same-day sale. Dates and per-transaction proceeds are listed for each sale in the excerpt.
Hims & Hers Health, Inc. entered into a Master Receivables Purchase Agreement allowing its subsidiaries XeCare LLC and Apostrophe Pharmacy LLC to sell eligible receivables to JPMorgan Chase Bank for cash, subject to a $400,000,000 facility limit. The arrangement has an initial 364‑day term and can be extended by mutual agreement. The company provided a Performance Undertaking guaranteeing the subsidiaries’ performance under the agreement, but not the collectability of receivables.
The company also executed Amendment No. 4 to its Revolving Credit and Guaranty Agreement to permit the receivables program, add a new permitted indebtedness basket up to $400,000,000 related to the facility, and align lien and collateral provisions. Other loan terms, including interest, fees, covenants and events of default, remain unchanged.
Hims & Hers Health, Inc. Chief Medical Officer Patrick Harrison reported an open-market sale of Class A Common Stock. He sold 23,726 shares at a price of $35.00 per share. After this transaction, he directly holds 181,861 shares of the company’s Class A Common Stock.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported an exercise of stock options and a sale of common shares. He exercised 6,376 shares of Class A common stock at $5.01 per share and sold 18,197 shares at an average price of $34.0285 per share. The filing states these option exercises and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025. Following the transactions, Okupe directly holds 284,321 shares of Class A common stock and indirectly holds 7,853 shares through the Oluyemi Okupe Separate Property Trust.